KONDOR LIMITED

1. Financial Health Score: B (Good, with Transitional Monitoring Required)

Explanation: Kondor Limited receives a 'B' grade because its administrative and regulatory vital signs are robust—the patient is breathing steadily and complying with all statutory requirements. However, the recent, significant changes in ownership and directorship present as a recent "surgery" (acquisition). While the patient has survived the procedure and is recovering, the long-term financial prognosis depends on the strategic intent of the new parent company and the financial structures they introduce. The absence of current detailed financial "blood work" (balance sheet and P&L metrics) in this specific review prevents a perfect score.

2. Key Vital Signs

• Compliance Pulse (Filing Status): Strong and steady. The company’s accounts are made up to March 2025 and are not overdue, nor is the confirmation statement. This indicates a healthy administrative heartbeat with no signs of regulatory distress or fever.
• Corporate DNA (Ownership & Control): Mutated. The People with Significant Control (PSC) is listed as "Kondor Bidco Limited," which owns more than 75% of the shares. The term "Bidco" (Bid Company) is the classic genetic marker of a leveraged buyout or acquisition vehicle. The company is no longer independent; its financial bloodstream is now intravenously linked to a larger corporate parent.
• Leadership Neurology (Directorate): Recent transplant. Between October 2025 and March 2026, three directors resigned (including two British nationals), and two new Irish nationals were appointed. This represents a near-complete replacement of the board, confirming that new management is at the helm.
• Corporate Age & Lineage: Mature. Incorporated in 2000, this is a 24-year-old entity. It changed its name from Middleseries Limited shortly after birth—a standard formation practice—and has operated as a specialized sales agent (SIC 46180) for over two decades.
• Capital Anatomy: Nominal. The share capital of £2,093.07 is relatively small, which is typical for a private limited company acting as a subsidiary or holding vehicle, rather than a heavily capitalised operating entity.

3. Diagnosis

The patient is not suffering from an organic, operational illness; rather, it is experiencing the expected physiological shifts following a corporate acquisition.

The presence of a "Bidco" as the majority shareholder, coupled with the systematic replacement of the board of directors, is the textbook presentation of a corporate buyout. The previous management team has been discharged, and a new team—likely appointed by the acquiring parent—has taken over primary care of the business.

Because the company files as "Total Exemption Full," it is classified as small and does not file a detailed profit and loss account. Therefore, we cannot measure the thickness of its financial blood (profit margins, cash flow, debt levels) from the exterior. However, the structural symptoms—specifically, the shift to a "Bidco" structure—often introduce leveraged debt onto the balance sheet. The patient's future health is now entirely dependent on the financial wellness and strategic objectives of its new parent.

4. Prognosis

Future Outlook: Stable, but highly dependent on parent company strategy.

The immediate risk of administrative failure (dissolution, liquidation) is very low due to the backing of a corporate parent. However, "Bidco" structures often carry acquisition debt. If interest rates remain high, this debt could act as a chronic condition, restricting the company's ability to invest and grow. Conversely, if the new parent has acquired Kondor Limited to integrate it into a larger group, the company may eventually be merged (absorbed) and dissolved, meaning the patient as a standalone legal entity may eventually cease to exist.

5. Recommendations

To ensure long-term financial wellness, the following prescriptions are recommended:

1. Examine the Parent’s Blood Work: Because Kondor Limited's own accounts will now offer limited visibility, stakeholders must review the consolidated accounts of "Kondor Bidco Limited" to understand the true debt load and financial pressure being applied to the subsidiary.
2. Monitor for Integration Side Effects: With new Irish directors at the helm, watch for signs of strategic shifts. Is the company being prepared for growth, or is it being streamlined for a future resale? Changes in trading patterns, supplier terms, or staff turnover are key symptoms to monitor.
3. Maintain Statutory Hygiene: The new board must ensure that the company’s registered details and internal governance are updated smoothly post-transition. A failure to maintain basic filing hygiene under new ownership is an early warning sign of administrative neglect.